Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: A multicenter study

Journal of Endocrinological Investigation

Volumn 29, Issue 5, 2006, Pages 427-437

  Papi, Giampaolo ^a,e   Corsello, S M ^b   Cioni, K ^a   Pizzini, A M ^c   Corrado, S ^a   Carapezzi, C ^c   Fadda, G ^b   Baldini, A ^c   Carani, C ^a,e   Pontecorvi, A ^b   Roti, E ^d  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c AUSL Modena   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e Ospedale Ramazzino   (Italy)

Author keywords

Calcitonin; Fine needle aspiration cytology; Medullary thyroid carcinoma; Thyroid nodules

Indexed keywords

CALCITONIN; PENTAGASTRIN; TUMOR MARKER;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; ASPIRATION BIOPSY; CALCITONIN BLOOD LEVEL; CELL HYPERPLASIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC VALUE; FEMALE; GROUPS BY AGE; HEALTH CARE FACILITY; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT REFERRAL; PATIENT SELECTION; PREDICTION; PREOPERATIVE EVALUATION; PREVALENCE; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; THYROID MEDULLARY CARCINOMA; THYROID NODULE; THYROID SURGERY; THYROIDITIS; TREATMENT INDICATION;

EID: 33745912492     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03344126     Document Type: Article

References (44)

1. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993, 328: 553-9.
2. Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. Arch Intern Med 1996, 156: 2165-72.
3. Hegedus L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev 2003, 24: 102-32.
4. Hegedus L. The thyroid nodule. N Engl J Med 2004, 351: 1764-71.
5. Ezzat S, Sarti DA, Cain DR, Braunstein GD. Thyroid incidentalomas: prevalence by palpation and ultrasonography. Arch Intern Med 1994, 154: 1338-40.
6. Ross DS. Diagnostic approach to and treatment of thyroid nodules. UpToDate Clinical Reference Library 2001, 9: 3 -www.uptodate.com.
7. Heshmati HM, Gharib H, van Heerden JA, Sizemore GW. Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Am J Med 1997, 103: 60-9.
8. Murray D. The thyroid gland. In: Kovacs K, Asa S eds. Functional endocrine pathology. Vol. 1. Boston: Blackwell. 1991, 293-374.
9. Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A. RET: normal and abnormal functions. Endocrinology 2004, 145: 5448-51.
10. Gharib H, McConahey WM, Tiegs RD, et al. Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970. Mayo Clin Proc 1992, 67: 934-40.
11. Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000, 88: 1139-48.
12. Fleming JB, Lee JE, Bouvet M, et al. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg 1999, 230: 697-707.
13. Oertel YC, Oertel JE. Thyroid cytology and histology Baillieres Best Pract Res Clin Endocrinol Metab 2000, 14: 541-57.
14. Ravetto C, Colombo L, Dottorini ME. Usefulness of fine-needle aspiration in the diagnosis of thyroid carcinoma: a retrospective study in 37,895 patients. Cancer 2000, 90: 357-63.
15. Tashjian Jr AH, Howland BG, Melvin KEW, Hill CS Jr. Immunoassay of human calcitonin. Clinical measurement, relation to serum calcium and studies in patients with medullary thyroid carcinoma. N Engl J Med 1970, 283: 890-5.
16. Pacini F, Basolo F, Elisei R, Fugazzola L, Cola A, Pinchera A. Medullary thyroid cancer. An immunohistochemical and humoral study using six separate antigens. Am J Clin Pathol 1991, 95: 300-8.
17. Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004, 89: 163-8.
18. Karanikas G, Abbas M, Poetzi C, et al. Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects. J Clin Endocrinol Metab 2004, 89: 515-9.
19. Kotzmann H, Schmidt A, Scheuba C, et al. Basal calcitonin levels and the response to pentagastrin stimulation in patients after kidney transplantation or on chronic hemodialysis as indicators of medullary carcinoma. Thyroid 1999, 9: 943-7.
20. Santeusanio G, Iafrate E, Partenzi A, Mauriello A, Autelitano F, Spagnoli L. A critical reassessment of the concept of C-cell hyperplasia of the thyroid. Appl Immunohistochem 1997, 5: 160-72.
21. Gibson WG, Peng TC, Croker BP. Age-associated C-cell hyperplasia in the human thyroid. Am J Pathol 1982, 106: 388-93.
22. Hodak SP, Burman KD. The calcitonin conundrum - Is it time for routine measurement of serum calcitonin in patients with thyroid nodules? J Clin Endocrinol Metab 2004, 89: 511-4.
23. Deftos LJ. Should serum calcitonin be routinely measured in patients with thyroid nodules-Will the law answer before endocrinologists do? J Clin Endocrinol Metab 2004, 89: 4768-9.
24. Castro R, Gharib H. Continuing controversy in the management of thyroid nodules. Ann Intern Med 2005, 42: 926-31.
25. Rosai J, Carcangiu ML, DeLellis RA. Tumors of the thyroid gland. 3rd series. Fascicle 5. AFIP. Washington DC: Armed Forces Institute of Pathology. 1990, 223-9.
26. Shah JP, Kian K, Forastiere A, et al. American Joint Committee on Cancer. Cancer staging manual. 6th ed. New York: Springer-Verlag. 2002, 77-87.
27. Papi G, Corrado S, Pomponi MG, Carapezzi C, Cesinaro A, LiVolsi VA. Concurrent lymph node metastases of medullary and papillary thyroid carcinoma in a case with RET oncogene germline mutation. Endocr Pathol 2003, 14: 269-76.
28. Pacini F, Fontanelli M, Fugazzola L, et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1994, 78: 826-9.
29. Rieu M, Lame MC, Richard A, et al. Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clin Endocrinol (Oxf) 1995, 42: 453-60.
30. Niccoli P, Wion-Barbot N, Caron P, et al. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. J Clin Endocrinol Metab 1997, 82: 338-41.
31. Vierhapper H, Raber W, Bieglmayer C, Kaserer K, Weinhausl A, Niederle B. Routine measurement of plasma calcitonin in nodular thyroid diseases. J Clin Endocrinol Metab 1997, 82: 1589-93.
32. Eng C. The RET proto-oncongene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. N Engl J Med 1996, 335: 943-51.
33. Komminoth P. The RET proto-oncogene in medullary and papillary thyroid carcinoma. Virchows Arch 1997, 431: 1-9.
34. Tommasi M, Brocchi A, Cappellini A, Raspanti S, Mannelli M. False serum calcitonin high levels using a non-competitive two-site IRMA. J Endocrinol Invest 2001, 24: 356-60.
35. Bieglmayer C, Niederle B, Vierhapper H. Interference causes false high calcitonin levels with a commercial assay. J Endocrinol Invest 2002, 25: 197.
36. Engelbach M, Gorges R, Forst T, et al. Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. J Clin Endocrinol Metab 2000, 85: 1890-4.
37. Sheuba C, Kaserer K, Weinhausl A, et al. Is medullary thyroid cancer predictable? A prospective study of 86 patients with abnormal pentagastrin tests. Surgery 1999, 126: 1089-95.
38. Rosai J. Surgical Pathology. New York: Mosby. 9th ed. 2004, 557.
39. Perry A, Molberg K, Albores-Saavedra J. Physiologic versus neoplastic C-cell hyperplasia of the thyroid: separation of distinct histologic and biologic entities. Cancer 1996, 77: 750-6.
40. Guyetant S, Wion-Barbot N, Rousselet MC, Franc B, Bigorgne JC, Saint-Andre JP. C-cell hyperplasia associated with chronic lymphocytic thyroiditis: a retrospective quantitative study of 112 cases. Hum Pathol 1994, 25: 514-21.
41. Barbot N, Guyetant S, Beldent V, et al. Chronic autoimmune thyroiditis and C-cell hyperplasia. Study of calcitonin secretion in 24 patients. Ann Endocrinol (Paris) 1991, 52: 109-12.
42. Biddinger PW, Brennan MF, Rosen PP. Symptomatic C-cell hyperplasia associated with chronic lymphocytic thyroiditis. Am J Surg Pathol 1991, 15: 599-604.
43. Holm LE, Blomgren H, Lowhagen T. Cancer risks in chronic lymphocytic thyroiditis. N Engl J Med 1985, 312: 601-4.
44. Taruscio D, Cerbo M. Rare diseases: general principle, specific problems, and health interventions. Ann Ist Super Sanita 1999, 35: 237-44.